Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab.
Indian J Nephrol
; 34(2): 191-194, 2024.
Article
en En
| MEDLINE
| ID: mdl-38681007
ABSTRACT
Posttransplant thrombotic microangiopathy (PT-TMA) can be caused by calcineurin inhibitors (CNIs), ischemic injury, infections, or antibody-mediated rejection (ABMR). Delayed recognition can result in allograft loss. We describe the first reported case of successful reversal of refractory PT-TMA with eculizumab in India. It highlights the importance of prompt diagnosis and benefit from an early initiation of eculizumab therapy in refractory cases.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Año:
2024
Tipo del documento:
Article